Vapotherm's Asthma Therapy More Effective Than Standard Oxygen Therapy In Kids
Portfolio Pulse from Vandana Singh
Vapotherm Inc (NASDAQ:VAPO) announced the results of a clinical trial showing its high flow humidified oxygen therapy to be more effective than standard oxygen therapy in treating children with acute severe asthma. The study found that fewer children treated with Vapotherm's therapy required escalation of treatment and met hospital discharge criteria sooner. Despite the positive trial results, VAPO shares are down 3.85%.
September 25, 2023 | 8:16 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Vapotherm's clinical trial results show its asthma therapy to be more effective than standard treatment. Despite this, VAPO shares have fallen 3.85%.
The positive clinical trial results should have been a positive catalyst for VAPO's stock. However, the stock has fallen, suggesting other factors are influencing its price. This could be due to broader market conditions or specific issues related to the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100